首页> 外文期刊>Journal of Cancer Research and Therapeutics >Role of surgical treatment for hepatolithiasis-associated intrahepatic cholangiocarcinoma: A retrospective study in a single institution
【24h】

Role of surgical treatment for hepatolithiasis-associated intrahepatic cholangiocarcinoma: A retrospective study in a single institution

机译:外科治疗在肝结石相关肝内胆管癌中的作用:单个机构的回顾性研究

获取原文
       

摘要

Context: The extent of hepatectomy and lymph node dissection (LND) in the treatment of hepatolithiasis-associated intrahepatic cholangiocarcinoma (HL-iCCA) is still controversial. Aims: The aim of this retrospective study was to evaluate the role of surgical treatment for HL-iCCA. Methods: The clinical data of 63 patients with HL-iCCA who undergoing surgery between January 2005 and December 2015 were analyzed retrospectively. Statistical Analysis Used: All data were analyzed by the SPSS 17.0 software program (IMB Inc., Chicago, IL, USA). Survival curves were analyzed by the Kaplan–Meier method and compared by the Log-rank test. A P Results: Forty-nine patients (77.8%) underwent surgical resection including 35 with LND and 14 without LND. The overall 1-, 3-, and 5-year survival rates were 58.1%, 28.2%, and 10.6%, respectively, and the median survival time was 19 months. The 1-, 3-, and 5-year survival rates of resection group were 78.9%, 36.3%, and 13.5%, respectively, while the 1-year survival rate of exploratory laparotomy group was 0 (P P = 0.043). According to the N status, the 1-, 3-, and 5-year survival rates of pN0 subgroup were 81.8%, 49.2%, and 28.1%; pN1 subgroup were 65.3%, 18.6%, and 0%; and pNx subgroup were 71.4%, 17.9%, and 0%, respectively (pN0 vs. pN1, P = 0.005; pN0 vs. pNx, P = 0.004; pN1 vs. pNx, P = 0.653). The 1-, 3-, and 5-year survival rates of R0 resection (n = 42) were 80.2%, 36.7%, and 14.9%, respectively, and those of R1 resection (n = 7) were 71.4%, 0%, and 0%, respectively (P = 0.028). Conclusions: Radical resection is the most effective therapy for HL-iCCA. Regional lymphadenectomy is strongly recommended in resectable HL-iCCA, which is helpful in tumor staging and long-term survival.
机译:背景:肝切除和淋巴结清扫术(LND)在治疗肝结石相关的肝内胆管癌(HL-iCCA)的程度方面仍存在争议。目的:这项回顾性研究的目的是评估手术治疗对HL-iCCA的作用。方法:回顾性分析2005年1月至2015年12月行手术治疗的63例HL-iCCA患者的临床资料。使用的统计分析:所有数据均通过SPSS 17.0软件程序(IMB Inc.,美国伊利诺伊州芝加哥)进行分析。生存曲线通过Kaplan-Meier方法进行分析,并通过对数秩检验进行比较。结果:四十九例患者(77.8%)接受了手术切除,其中包括LND 35例和LND 14例。 1年,3年和5年总生存率分别为58.1%,28.2%和10.6%,中位生存时间为19个月。切除组的1年,3年和5年生存率分别为78.9%,36.3%和13.5%,而探索性剖腹手术组的1年生存率为0(P P = 0.043)。根据N状态,pN0亚组的1、3和5年生存率分别为81.8%,49.2%和28.1%; pN1亚组分别为65.3%,18.6%和0%;和pNx子组分别为71.4%,17.9%和0%(pN0对pN1,P = 0.005; pN0对pNx,P = 0.004; pN1对pNx,P = 0.653)。 R0切除术(n = 42)的1年,3年和5年生存率分别为80.2%,36.7%和14.9%,R1切除术(n = 7)的1、3和5年生存率分别为71.4%,0% ,分别为0%(P = 0.028)。结论:根治性切除是治疗HL-iCCA的最有效方法。强烈建议在可切除的HL-iCCA中进行局部淋巴结清扫术,这有助于肿瘤分期和长期生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号